As Regeneron’s Eylea continues its reign as one of the best-selling drugs in the world, the company’s executives have been on the receiving end of massive pay packages. For CEO Len Schleifer, 2018 was no different. More: With Eylea still
read moreBiogen has faced rebellious investors before. Ten years ago, it confronted a proxy fight with activist Carl Icahn that ended with two new directors on its board. So in a way, it’s no surprise the biotech is expanding its board
read moreThe approval is for adjunct use to insulin therapy to improve blood sugar control in adults. More: Zynquista approved in EU for certain patients with type I diabetes Source: News
read moreThe ELLIPSE trial is the first Phase III trial completed in over a decade in children and adolescents with type II diabetes. More: Novo Nordisk’s Victoza found to cut blood sugar in children Source: News
read moreThe approval was based on data from ODYSSEY OUTCOMES. More: Praulent gets FDA nod for heart attack and stroke Source: News
read moreThirteen medicines were recommended for approval at the committee’s April 2019 meeting. More: Pfizer’ Talzenna leads latest CHMP highlights Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals